PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New guideline emphasizes conversations about mood, mental health between patients and clinicians

Canadian Task Force on Preventive Health Care releases guideline on screening adults for depression with screening tool

2025-10-20
(Press-News.org) Depression is a mental illness, and support for depression can improve emotions, thoughts, and well-being. A new guideline from the Canadian Task Force on Preventive Health Care recommends that patients aged 18 and older talk to their health care providers about depression rather than undergo routine screening with standard tools, like questionnaires. The guideline is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250237.

In Canada, depression is common, with about 1 in 10 people (without bipolar disorder) experiencing depression in their lifetimes. It negatively affects how a person feels, thinks, or behaves and can be linked to thoughts of suicide. Since 2012, rates of depression have risen in people aged 15 years and older. People who experienced childhood trauma, have chronic disease, are Indigenous, identify as 2SLGBTQIA+, or have substance use disorders at higher risk of depression.

“Depression is a medical illness that can significantly affect people’s health and well-being,” said Task Force member Dr. Eddy Lang, an emergency physician at the University of Calgary and chair of the guideline working group. “It is important for clinicians to be vigilant and ask about their patients’ mental health as part of usual care, and for patients to understand the importance of talking about mental health with their health care providers.”

As depression is often diagnosed, managed, and treated in primary care, the guideline is targeted at physicians, nurses, and other health professionals who may be the first point of contact for care. Its aim is to provide guidance to clinicians for adults aged 18 years and older at normal risk of depression as well as those at higher risk due to childhood trauma, family history, and other factors. The guideline does not apply to people with a history of depression, diagnosis or symptoms of depression, or other mental illnesses.

The Canadian Task Force on Preventive Health Care recommends against routine screening for depression using standardized tools like questionnaires in all adults aged 18 years and older. Instead, it emphasizes clinical vigilance and discussions about mental health between patients and their health care providers.

“The task force did not find evidence that taking a blanket approach and screening every adult for depression with a questionnaire would lead to better mental health,” said Dr. Brett Thombs, a clinical expert on the guideline and Canada Research Chair and professor in the Faculty of Medicine at McGill University and the Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec. “It would, though, require massive resources to do this in our health clinics, and we need those resources to help reduce the substantial challenges that people who want help face when accessing mental health care in Canada. The task force wisely recommended awareness and conversations between patients and their health care providers but not a screening intervention that would place additional burden on the health care system without benefit.”

In making this recommendation, the task force considered the challenges facing Canada’s primary health care system, and the burden of engaging in activities that consume scarce resources or might limit access to primary care providers, especially when there is a lack of effectiveness above usual care.

“It is important for patients to understand the value of talking about mental health with their health care providers, and we hope this guideline provides a path for clinicians to support their patients,” said Dr. Lang.

The guideline working group included 3 external clinical and content experts; a researcher with expertise in mental health and depression screening; a physician–scientist expert in psychiatry, including depression management in primary care; and another psychiatrist with expertise in prevalence of mental health disorders and risk factors. The working group also engaged members of the public who have experienced depression or are in the target group for input. Many interest holders also provided input to the guideline.

This update to the 2013 guideline contains related tools to help clinicians and patients. Find public infographic, clinician infographic, podcast and more on October 20.

END


ELSE PRESS RELEASES FROM THIS DATE:

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

2025-10-20
Philadelphia, October 20, 2025 – Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants may lower their risk of developing this allergy. Now, a new study from researchers from Children’s Hospital of Philadelphia (CHOP) has shown that the rates of diagnosis of peanut and other IgE-mediated food allergies have declined since the adoption of guidelines encouraging early introduction practices. The findings, published today ...

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

2025-10-19
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway VT3989 was awarded Orphan Drug Designation and Fast Track Designation for the treatment of mesothelioma by the FDA BERLIN, OCTOBER 19, 2025 ― The first-in-class YAP-TEAD inhibitor ...

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

2025-10-19
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found. The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to “wake up” the immune system against cancer. Building on a previous UF study, the observation also marks a significant step toward a long-awaited universal cancer vaccine to ...

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

2025-10-19
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after treatment as those who never received a vaccine These findings have prompted a randomized Phase III trial to determine if mRNA COVID vaccines should be part of the standard of care for this type of therapy If validated, findings could significantly increase the number of patients who benefit from immunotherapy BERLIN, OCTOBER 19, 2025 ― Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning ...

Drug combo cuts risk of death in advanced prostate cancer by 40%

2025-10-19
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination therapy, which adds a drug called enzalutamide to commonly prescribed hormone therapy, reduced deaths in patients with recurrent prostate cancer after surgery or radiation for whom other treatments are no longer an option. The trial results were published in The New England Journal of Medicine (NEJM) with simultaneous presentation during the European Society for Medical Oncology Congress (ESMO) Oct. 19 in Berlin. “After ...

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

2025-10-19
BERLIN October 19, 2025 – Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy. These findings, which stem from the ASCENT-03 trial in triple-negative breast cancer co-led by investigators at Dana-Farber Cancer Institute, are presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. They are also published simultaneously in the New England Journal ...

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

2025-10-18
BERLIN October 18, 2025 – Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany. Tumors that express the estrogen receptor (ER) account for roughly 70% ...

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

2025-10-18
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal paraganglia Study found belzutifan shrank tumors and improved symptoms without surgery Belzutifan is the first oral and only FDA-approved treatment for patients with advanced, inoperable, or metastatic PPGL FDA granted approval for treating PPGL in May 2025 based on these trial results BERLIN, OCTOBER 18, 2025 – A multicenter Phase II clinical ...

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

2025-10-18
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression First head-to-head study comparing second-line treatments lenvatinib plus everolimus vs. cabozantinib Combination offers option for patients with metastatic clear-cell renal carcinoma (ccRCC) who experience disease progression following first-line immunotherapy BERLIN, OCTOBER 18, 2025 ― Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney ...

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

2025-10-18
Lugano/Berlin 18 October 2025 - In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.   The results from the phase III DESTINY-Breast05 and DESTINY-Breast11 trials, presented in a Presidential Symposium, mark a paradigm shift in breast cancer treatment, positioning ADCs not only as powerful therapeutic agents when the disease has already progressed but also as potential new standards of care in patients with early disease (1,2).    “There is ...

LAST 30 PRESS RELEASES:

Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer

Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer

What is the extent of disparities in cancer clinical trials among low- and middle-income countries?

Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns

Nearly half of Finns with chronic conditions find medication therapy a burden

Do animals fall for optical illusions? What fish and birds can teach us about perception

New guideline emphasizes conversations about mood, mental health between patients and clinicians

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

Drug combo cuts risk of death in advanced prostate cancer by 40%

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

Sylvester Cancer Tip Sheet for October 2025

Three science and technology leaders elected to Hertz Foundation Board of Directors

Jump Trading CSO Kevin Bowers elected to Hertz Foundation Board of Directors

Former Inscripta CEO Sri Kosaraju elected to Hertz Foundation Board of Directors

Citadel’s Jordan Chetty elected to Hertz Foundation Board of Directors

McGill research flags Montreal snow dump, inactive landfills as major methane polluters

A lightweight and rapid bidirectional search algorithm

Eighty-five years of big tree history available in one place for the first time

MIT invents human brain model with six major cell types to enable personalized disease research, drug discovery

Health and economic air quality co-benefits of stringent climate policies

How immune cells deliver their deadly cargo

How the brain becomes a better listener: How focus enhances sound processing

Processed fats found in margarines unlikely to affect heart health

[Press-News.org] New guideline emphasizes conversations about mood, mental health between patients and clinicians
Canadian Task Force on Preventive Health Care releases guideline on screening adults for depression with screening tool